101
|
Alpízar A, Marino F, Ramos-Fernández A, Lombardía M, Jeko A, Pazos F, Paradela A, Santiago C, Heck AJR, Marcilla M. A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens. Mol Cell Proteomics 2016; 16:181-193. [PMID: 27920218 DOI: 10.1074/mcp.m116.063800] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2016] [Revised: 11/16/2016] [Indexed: 01/04/2023] Open
Abstract
As aberrant protein phosphorylation is a hallmark of tumor cells, the display of tumor-specific phosphopeptides by Human Leukocyte Antigen (HLA) class I molecules can be exploited in the treatment of cancer by T-cell-based immunotherapy. Yet, the characterization and prediction of HLA-I phospholigands is challenging as the molecular determinants of the presentation of such post-translationally modified peptides are not fully understood. Here, we employed a peptidomic workflow to identify 256 unique phosphorylated ligands associated with HLA-B*40, -B*27, -B*39, or -B*07. Remarkably, these phosphopeptides showed similar molecular features. Besides the specific anchor motifs imposed by the binding groove of each allotype, the predominance of phosphorylation at peptide position 4 (P4) became strikingly evident, as was the enrichment of basic residues at P1. To determine the structural basis of this observation, we carried out a series of peptide binding assays and solved the crystal structures of HLA-B*40 in complex with a phosphorylated ligand or its nonphosphorylated counterpart. Overall, our data provide a clear explanation to the common motif found in the phosphopeptidomes associated to different HLA-B molecules. The high prevalence of phosphorylation at P4 is dictated by the presence of the conserved residue Arg62 in the heavy chain, a structural feature shared by most HLA-B alleles. In contrast, the preference for basic residues at P1 is allotype-dependent and might be linked to the structure of the A pocket. This molecular understanding of the presentation of phosphopeptides by HLA-B molecules provides a base for the improved prediction and identification of phosphorylated neo-antigens, as potentially used for cancer immunotherapy.
Collapse
Affiliation(s)
- Adán Alpízar
- From the ‡Proteomics Unit, Spanish National Biotechnology Centre (CSIC), Darwin 3, 28049, Madrid, Spain
| | - Fabio Marino
- §Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Science Faculty, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands.,¶Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, the Netherlands
| | - Antonio Ramos-Fernández
- ‖Proteobotics SL, Spanish National Biotechnology Centre (CSIC), Darwin 3, 28049, Madrid, Spain
| | - Manuel Lombardía
- From the ‡Proteomics Unit, Spanish National Biotechnology Centre (CSIC), Darwin 3, 28049, Madrid, Spain
| | - Anita Jeko
- §Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Science Faculty, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands.,¶Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, the Netherlands
| | - Florencio Pazos
- **Computational Systems Biology Group, Spanish National Biotechnology Centre (CSIC), Darwin 3, 28049, Madrid, Spain
| | - Alberto Paradela
- From the ‡Proteomics Unit, Spanish National Biotechnology Centre (CSIC), Darwin 3, 28049, Madrid, Spain
| | - César Santiago
- ‡‡Macromolecular X-ray Crystallography Unit, Spanish National Biotechnology Centre (CSIC), Darwin 3, 28049, Madrid, Spain
| | - Albert J R Heck
- §Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Science Faculty, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands; .,¶Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, the Netherlands
| | - Miguel Marcilla
- From the ‡Proteomics Unit, Spanish National Biotechnology Centre (CSIC), Darwin 3, 28049, Madrid, Spain;
| |
Collapse
|
102
|
Abstract
Pancreatic cancer (PC) is a lethal disease representing the seventh most frequent cause of death from cancer worldwide. Resistance of pancreatic tumors to current treatments leads to disappointing survival rates, and more specific and effective therapies are urgently needed. In recent years, immunotherapy has been proposed as a promising approach to the treatment of PC, and encouraging results have been published by various preclinical and clinical studies. This review provides an overview of the latest developments in the immunotherapeutic treatment of PC and summarizes the most recent and important clinical trials.
Collapse
|
103
|
Veluchamy JP, Heeren AM, Spanholtz J, van Eendenburg JDH, Heideman DAM, Kenter GG, Verheul HM, van der Vliet HJ, Jordanova ES, de Gruijl TD. High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunol Immunother 2016; 66:51-61. [PMID: 27783105 PMCID: PMC5222919 DOI: 10.1007/s00262-016-1919-1] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Accepted: 10/14/2016] [Indexed: 11/28/2022]
Abstract
Down-regulation of HLA in tumor cells, low numbers and dysfunctionality of NK cells are commonly observed in patients with end-stage cervical cancer. Adoptive transfer of high numbers of cytotoxic NK cells might be a promising treatment approach in this setting. Here, we explored the cytotoxic efficacy on ten cervical cancer cell lines of activated allogeneic NK cells from two sources, i.e., peripheral blood (PBNK) with and without cetuximab (CET), a tumor-specific monoclonal antibody directed against EGFR, or derived from umbilical cord blood (UCB-NK). Whereas CET monotherapy was ineffective against the panel of cervical cancer cell lines, irrespective of their EGFR expression levels and despite their RASwt status, it significantly enhanced the in vitro cytotoxic efficacy of activated PBNK (P = 0.002). Equally superior cytotoxicity over activated PBNK alone was achieved by UCB-NK (P < 0.001). Both PBNK- and UCB-NK-mediated cytotoxic activity was dependent on the NK-activating receptors natural killer group 2, member D receptor (NKG2D) and DNAX accessory molecule-1 (DNAM-1) (P < 0.05) and unrelated to expression levels of the inhibitory receptors HLA-E and/or HLA-G. Most strikingly, whereas the PBNK’s cytotoxic activity was inversely correlated with HLA-ABC levels (P = 0.036), PBNK + CET and UCB-NK cytotoxicity were entirely independent of HLA-ABC expression. In conclusion, this study provides a rationale to initiate a clinical trial for cervical cancer with adoptively transferred allogeneic NK cells, employing either UCB-NK or PBNK + CET for EGFR-expressing tumors. Adoptive transfer of UCB-NK might serve as a generally applicable treatment for cervical cancer, enabled by HLA-, histology- and HPV-independent killing mechanisms.
Collapse
Affiliation(s)
- John P Veluchamy
- Department of Medical Oncology, VU (Vrije Universiteit) University Medical Center-Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.,Glycostem Therapeutics, Oss, The Netherlands
| | - A Marijne Heeren
- Department of Medical Oncology, VU (Vrije Universiteit) University Medical Center-Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.,Department of Obstetrics and Gynecology, Center Gynecological Oncology Amsterdam (CGOA), VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | | | - Jaap D H van Eendenburg
- Department of Pathology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands
| | - Daniëlle A M Heideman
- Department of Pathology, VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - Gemma G Kenter
- Department of Obstetrics and Gynecology, Center Gynecological Oncology Amsterdam (CGOA), VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - Henk M Verheul
- Department of Medical Oncology, VU (Vrije Universiteit) University Medical Center-Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - Hans J van der Vliet
- Department of Medical Oncology, VU (Vrije Universiteit) University Medical Center-Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - Ekaterina S Jordanova
- Department of Obstetrics and Gynecology, Center Gynecological Oncology Amsterdam (CGOA), VU University Medical Center, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
| | - Tanja D de Gruijl
- Department of Medical Oncology, VU (Vrije Universiteit) University Medical Center-Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
| |
Collapse
|
104
|
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res 2016; 2016:8941260. [PMID: 27314056 PMCID: PMC4893440 DOI: 10.1155/2016/8941260] [Citation(s) in RCA: 163] [Impact Index Per Article: 20.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2016] [Accepted: 04/28/2016] [Indexed: 12/31/2022] Open
Abstract
The adaptive immune system plays a pivotal role in the host's ability to mount an effective, antigen-specific immune response against tumors. CD8(+) tumor-infiltrating lymphocytes (TILs) mediate tumor rejection through recognition of tumor antigens and direct killing of transformed cells. In growing tumors, TILs are often functionally impaired as a result of interaction with, or signals from, transformed cells and the tumor microenvironment. These interactions and signals can lead to transcriptional, functional, and phenotypic changes in TILs that diminish the host's ability to eradicate the tumor. In addition to effector and memory CD8(+) T cells, populations described as exhausted, anergic, senescent, and regulatory CD8(+) T cells have been observed in clinical and basic studies of antitumor immune responses. In the context of antitumor immunity, these CD8(+) T cell subsets remain poorly characterized in terms of fate-specific biomarkers and transcription factor profiles. Here we discuss the current characterization of CD8(+) T cell fates in antitumor immune responses and discuss recent insights into how signals in the tumor microenvironment influence TIL transcriptional networks to promote CD8(+) T cell dysfunction.
Collapse
|
105
|
Jiang Z, Zhang H, Wang Y, Yu B, Wang C, Liu C, Lu J, Chen F, Wang M, Yu X, Lin J, Pan X, Wang P, Zhu H. Altered Hepa1-6 cells by dimethyl sulfoxide (DMSO)-treatment induce anti-tumor immunity in vivo. Oncotarget 2016; 7:9340-52. [PMID: 26824185 PMCID: PMC4891044 DOI: 10.18632/oncotarget.7009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 01/01/2016] [Indexed: 12/30/2022] Open
Abstract
Cancer immunotherapy is the use of the immune system to treat cancer. Our current research proposed an optional strategy of activating immune system involving in cancer immunotherapy. When being treated with 2% DMSO in culture medium, Hepa1-6 cells showed depressed proliferation with no significant apoptosis or decreased viability. D-hep cells, Hepa1-6 cells treated with DMSO for 7 days, could restore to the higher proliferation rate in DMSO-free medium, but alteration of gene expression profile was irreversible. Interestingly, tumors from D-hep cells, not Hepa1-6 cells, regressed in wild-type C57BL/6 mice whereas D-hep cells exhibited similar tumorigenesis as Hep1–6 cells in immunodeficient mice. As expected, additional Hepa1-6 cells failed to form tumors in the D-hep-C57 mice in which D-hep cells were eliminated. Further research confirmed that D-hep-C57 mice established anti-tumor immunity against Hepa1-6 cells. Our research proposed viable tumor cells with altered biological features by DMSO-treatment could induce anti-tumor immunity in vivo.
Collapse
Affiliation(s)
- Zhengyu Jiang
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China.,Department of Anesthesiology, Second Military Medical University, Shanghai, P.R. China
| | - Hongxia Zhang
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| | - Ye Wang
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| | - Bin Yu
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| | - Chen Wang
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| | - Changcheng Liu
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| | - Juan Lu
- Training Department, Second Military Medical University, Shanghai, P.R. China
| | - Fei Chen
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| | - Minjun Wang
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| | - Xinlu Yu
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| | - Jiahao Lin
- School of Clinic Medicine, Second Military Medical University, Shanghai, P.R. China
| | - Xinghua Pan
- Department of Genetics, Yale University School of Medicine, New Haven, CT, USA
| | - Pin Wang
- National Key Laboratory of Medical Immunology and Institute of Immunology, Second Military Medical University, Shanghai, P.R. China
| | - Haiying Zhu
- Department of Cell Biology, Second Military Medical University, Shanghai, P.R. China.,Center for Stem Cell and Medicine, The Graduate School, Second Military Medical University, Shanghai, P.R. China
| |
Collapse
|